Bicara Therapeutics SEC Filings

Bicara Therapeutics (BCAX) CEO reported a Form 4 for transactions on October 16, 2025. The executive exercised 24,103 stock options at $3.7898 per share and sold 24,103 common shares at a $18.8259 weighted average price, executed under a Rule 10b5-1 trading plan adopted on February 12, 2025.

After these transactions, the reporting person beneficially owns 309,892 common shares directly and 277,270 derivative securities (options) remain beneficially owned. The sale price ranged from $18.73 to $19.17. The option underlying the exercised shares vests in sixteen equal quarterly installments following August 8, 2023.

Bicara Therapeutics (BCAX) reported insider transactions by its President & COO (also a Director) on 10/15/2025. The officer exercised a stock option for 8,000 shares at an exercise price of $3.7898 and then sold 8,000 shares and an additional 4,500 shares at a weighted average price of $18.1554 (sales occurred between $18.00 and $18.34), executed pursuant to a Rule 10b5‑1 trading plan adopted on February 12, 2025.

Following these transactions, the reporting person beneficially owned 198,141 shares of common stock directly and held 157,334 derivative securities (stock options). The reported option was granted with a term through 08/08/2033 and vests in sixteen equal quarterly installments following 08/08/2023, subject to continued service.

Bicara Therapeutics (BCAX): CEO Form 4 activity. On 10/13/2025 and 10/15/2025, the CEO exercised stock options at $3.7898 per share for 11,445 and 13,289 shares, then sold the same amounts at weighted average prices of $18.9205 and $18.842, respectively. These transactions were executed under a Rule 10b5-1 trading plan adopted on February 12, 2025. Following the trades, the CEO directly owned 309,892 shares. The reported sale prices reflect weighted averages across ranges of $18.73–$19.635 and $18.73–$18.98.

Bicara Therapeutics (BCAX) Chief Medical Officer David Raben executed a pre-arranged Rule 10b5-1 plan on 10/09/2025 to exercise 22,000 stock options at an exercise price of $3.7898 and simultaneously sell 22,000 shares at $18.45. After these transactions his direct beneficial ownership in common stock declined from 57,497 to 35,497 shares, while he continues to hold options covering 22,000 shares and a total of 128,870 derivative shares outstanding following the transaction. The filing notes the 10b5-1 plan was adopted on 02/12/2025 and that option vesting began on 07/24/2024 with remaining vesting in quarterly installments through the schedule described.

Bicara Therapeutics CFO Ivan Hyep reported option exercise and share sales on 10/09/2025. The reporting person exercised a stock option with an $3.7898 exercise price for 6,415 shares, and those shares are the same 6,415 shares sold the same day under a Rule 10b5-1 trading plan at a weighted average price of $18.2278. Following the transactions, the CFO’s beneficial ownership fell from 151,770 shares to 145,355 shares. The option shares vest in sixteen equal quarterly installments beginning after 08/08/2023, subject to continued service. The filing was signed by an attorney-in-fact on 10/10/2025.

Bicara Therapeutics, Inc. (BCAX) filing a Form 144 reports a proposed sale of 6,415 common shares through UBS Financial Services on 10/09/2025 with an aggregate market value of $114,764.00. The shares were acquired the same day by exercise of stock options and paid for in cash. The filing also discloses sales by the same person, Ivan Hyep, in the three prior days: 6,514 shares on 10/06/2025 ($118,356.12), 18,244 shares on 10/07/2025 ($332,385.61), and 5,627 shares on 10/08/2025 ($102,456.42), totaling $553,198.15 in gross proceeds. The issuer had 54,562,841 shares outstanding and the proposed transactions are to occur on the NASDAQ.